文献速递泌尿生殖与妇科肿瘤放疗

高剂量率近距离放疗推量治疗前列腺癌:中低收入国家回顾性观察研究

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: A Retrospective Observational Study in Low- and Middle-Income Countries.
PubMed 文献 · Adv Radiat Oncol · 2025-07-16

该摩洛哥单中心回顾性研究纳入106例接受高剂量率近距离放疗推量联合外照射的中高危前列腺癌患者,中位随访26个月。3年总生存率87%、无转移生存率92%、生化无进展生存率78%;临床分期是唯一显著影响无转移生存的因素,晚期3级毒性发生率低。

要点

  • 3年总生存87%、无转移生存92%、生化无进展生存78%。
  • ISUP 1-3分者生化无进展生存85%、无转移生存92%,优于ISUP 4-5分者。
  • 晚期3级泌尿毒性1.89%、胃肠毒性0.94%,无3级急性毒性。

核心结论

  • 该单中心研究证实外照射联合近距离放疗推量治疗中高危前列腺癌有效且耐受性良好,即使晚期患者结果也令人鼓舞。
  • 临床分期被证明是无转移生存的主要预后因素。

研究设计与样本

  • 2014至2022年间单中心回顾性观察研究,共128例接受前列腺近距离放疗患者中纳入106例中高危且接受高剂量率近距离放疗推量的患者。
  • 84.91%患者接受激素治疗,中位随访26个月,分析临床特征、剂量学数据、毒性和肿瘤学结果。

主要发现

  • 106例中中危59例(55.66%)、高危47例(44.34%),局部晚期(T3a-T3b)占43.4%。
  • 3年总生存率87%、无转移生存率92%、生化无进展生存率78%。
  • 3年生化无进展生存率中危为75%、高危为70%。
  • ISUP 1-3分者生化无进展生存85%、无转移生存92%,ISUP 4-5分者分别为60%和79%。
  • 临床分期是唯一显著影响无转移生存的因素(P = .001)。

关键数值与推荐

  • 未报告3级急性泌尿或胃肠毒性。
  • 晚期3级毒性:泌尿1.89%、胃肠0.94%;2级毒性低于9%。

临床怎么用

  • 在中低收入国家背景下,外照射联合高剂量率近距离放疗推量可作为中高危前列腺癌的有效治疗选择。
  • 临床分期应作为预后分层的重要依据,尤其关注无转移生存。
  • 治疗相关3级毒性发生率低,支持该方案的耐受性。

局限性

  • 单中心回顾性研究设计。
  • 中位随访仅26个月,期限较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate brachytherapy used as an adjunct to external beam radiation therapy is recognized as an effective therapeutic approach in the treatment of intermediate and high-risk prostate cancer. However, data remain limited in African countries, particularly Morocco. The aim of this study was to assess the oncological outcomes and tolerability of boost brachytherapy in a Moroccan cohort. METHODS AND MATERIALS: A retrospective study was conducted between 2014 and 2022. Among 128 patients treated with prostate brachytherapy, 106 with intermediate- or high-risk prostate cancer who received high-dose-rate brachytherapy as a boost were included. Hormone therapy was administered to 84.91% of patients. Median follow-up was 26 months. Clinical characteristics, dosimetric data, toxicity, and oncological results were analyzed. RESULTS: Of the 106 patients, 59 (55.66%) had intermediate-risk cancer and 47 (44.34%) had high-risk cancer. Locally advanced stage (T3a-T3b) was observed in 43.4% of patients. At 3 years, overall survival, metastasis-free survival (MFS), and biochemical progression-free survival (BPFS) were 87%, 92%, and 78%, respectively. The 3-year BPFS was 75% for intermediate-risk cancers and 70% for high-risk cancers. International Society of Urological Pathology (ISUP)scores 1 to 3 showed better BPFS (85%) and MFS (92%) than ISUP scores 4 to 5 (BPFS: 60%, MFS: 79%). Clinical stage was the only significant factor for MFS (P = .001). No grade 3 acute toxicities (genitourinary or gastrointestinal) were reported. Late grade 3 toxicities were observed in 1.89% (genitourinary) and 0.94% (gastrointestinal) of patients. Grade 2 toxicities remained low (<9%). CONCLUSIONS: This single-center study confirms the efficacy and tolerability of the combination of external beam radiation therapy and brachytherapy in the treatment of intermediate- and high-risk prostate cancer. The results are encouraging, even in advanced-stage patients. Clinical stage has been shown to be the main prognostic factor for MFS.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Samlali H, Assaid N, Khobbaizi Y, et al. High-Dose-Rate Brachytherapy Boost for Prostate Cancer: A Retrospective Observational Study in Low- and Middle-Income Countries. Adv Radiat Oncol. 2025. PMID: 40989175. doi:10.1016/j.adro.2025.101861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。